IT1244697B - Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale - Google Patents

Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale

Info

Publication number
IT1244697B
IT1244697B ITMI910253A ITMI910253A IT1244697B IT 1244697 B IT1244697 B IT 1244697B IT MI910253 A ITMI910253 A IT MI910253A IT MI910253 A ITMI910253 A IT MI910253A IT 1244697 B IT1244697 B IT 1244697B
Authority
IT
Italy
Prior art keywords
prevention
treatment
ipriflavone
post
pharmaceutical association
Prior art date
Application number
ITMI910253A
Other languages
English (en)
Inventor
Paolo Chiesi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of ITMI910253A0 publication Critical patent/ITMI910253A0/it
Priority to ITMI910253A priority Critical patent/IT1244697B/it
Priority to IE021992A priority patent/IE920219A1/en
Priority to NZ241418A priority patent/NZ241418A/xx
Priority to AU11884/92A priority patent/AU1188492A/en
Priority to HU9302183A priority patent/HUT64848A/hu
Priority to PCT/EP1992/000174 priority patent/WO1992013538A1/en
Priority to EP92903484A priority patent/EP0569415A1/en
Priority to CA002101547A priority patent/CA2101547A1/en
Priority to ZA92661A priority patent/ZA92661B/xx
Publication of ITMI910253A1 publication Critical patent/ITMI910253A1/it
Application granted granted Critical
Publication of IT1244697B publication Critical patent/IT1244697B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Associazioni estemporanee e fisse di ipriflavone ed estrogeni naturali coniugati nella prevenzione e nel trattamento dell'osteoporosi post-menopausale presentano sorprendenti vantaggi.Si dimostra infatti che associando dosi terapeutiche di ipriflavone, agente terapeutico per l'osteoporosi, a dosi sub-attive di estrogeni naturali coniugati si incrementa l'efficacia dell'ipriflavone nei confronti della demineralizzazione ossea, assicurando contemporaneamente il controllo da parte degli estrogeni della sintomatologia tipica del climaterio.
ITMI910253A 1991-02-01 1991-02-01 Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale IT1244697B (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITMI910253A IT1244697B (it) 1991-02-01 1991-02-01 Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale
IE021992A IE920219A1 (en) 1991-02-01 1992-01-24 Pharmaceutical combination for the prevention and treatment¹of postmenopausal osteoporosis
NZ241418A NZ241418A (en) 1991-02-01 1992-01-27 Synergistic compositions comprising ipriflavone and at least one oestrogen
HU9302183A HUT64848A (en) 1991-02-01 1992-01-28 Medical preparatives for preventing and treating osteoporises after menopausa
AU11884/92A AU1188492A (en) 1991-02-01 1992-01-28 Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
PCT/EP1992/000174 WO1992013538A1 (en) 1991-02-01 1992-01-28 Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
EP92903484A EP0569415A1 (en) 1991-02-01 1992-01-28 Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
CA002101547A CA2101547A1 (en) 1991-02-01 1992-01-28 Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis
ZA92661A ZA92661B (en) 1991-02-01 1992-01-30 Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI910253A IT1244697B (it) 1991-02-01 1991-02-01 Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale

Publications (3)

Publication Number Publication Date
ITMI910253A0 ITMI910253A0 (it) 1991-02-01
ITMI910253A1 ITMI910253A1 (it) 1992-08-01
IT1244697B true IT1244697B (it) 1994-08-08

Family

ID=11358374

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI910253A IT1244697B (it) 1991-02-01 1991-02-01 Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale

Country Status (9)

Country Link
EP (1) EP0569415A1 (it)
AU (1) AU1188492A (it)
CA (1) CA2101547A1 (it)
HU (1) HUT64848A (it)
IE (1) IE920219A1 (it)
IT (1) IT1244697B (it)
NZ (1) NZ241418A (it)
WO (1) WO1992013538A1 (it)
ZA (1) ZA92661B (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6635994A (en) * 1993-04-16 1994-11-08 Tufts University School Of Medicine Method for treatment of menopausal and premenstrual symptoms
HU212932B (en) * 1993-08-02 1996-12-30 Chinoin Gyogyszer Es Vegyeszet Parmaceutical composition containing ipriflavone, hydroxyapatit and tricalciumphosphate for treating lack of bones and process for producing the composition
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
BR0208165A (pt) * 2001-03-16 2004-03-30 Wyeth Corp Composições farmacêuticas e seus usos na terapia de reposição de estrogênio
EP2415469A1 (en) * 2006-10-24 2012-02-08 David W. Krempin Anti-Resorptive and Bone Building Dietary Supplements and Methods of Use

Also Published As

Publication number Publication date
WO1992013538A1 (en) 1992-08-20
IE920219A1 (en) 1992-08-12
CA2101547A1 (en) 1992-08-02
ITMI910253A1 (it) 1992-08-01
ZA92661B (en) 1992-10-28
HU9302183D0 (en) 1993-10-28
NZ241418A (en) 1993-03-26
HUT64848A (en) 1994-03-28
EP0569415A1 (en) 1993-11-18
ITMI910253A0 (it) 1991-02-01
AU1188492A (en) 1992-09-07

Similar Documents

Publication Publication Date Title
NZ234051A (en) Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity
CY1105276T1 (el) Τριφασικο στοματικο αντισυλληπτικο
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
KR960704553A (ko) 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
CY2599B2 (en) Benzothiophene formulations of a specific dosage
CO5070665A1 (es) Composiciones de confiteria con centro relleno liquido, para el alivio del dolor o irritacion de la garganta y para el alivio de los conductos nasales, y pastillas de la garganta que las comprenden
CA2221753A1 (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
IT1244697B (it) Associazione farmaceutica per la prevenzione e il trattamento dell'osteoporosi post-menopausale
ES2173868T3 (es) Utilizacion de relaxina para la fabricacion de un medicamento destinado al tratamiento de enfermedades cardiovasculares.
NO178686C (no) Antikonsepsjonspakke for oral tilförsel
EE05259B1 (et) Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
ES2135342A1 (es) Procedimiento para prevenir el cancer de mama.
BR9712274A (pt) Composição hormonal consistindo de um composto de estrogênio e um composto progestacional
HUP9900612A2 (hu) Új hormonális gyógyászati készítmények, valamint a készítmények alkalmazása ösztrogénpótlásra
CY1108648T1 (el) Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
DE69430356D1 (de) Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
YU30103A (sh) Upotreba antiprogestina za profilaksu i lečenje hormonski zavisnih bolesti
UA28644A (uk) Спосіб лікування первинної аменореї центрального генезу у дівчат-підлітків
IT1243978B (it) Farmaco per uso umano, ad azione contraccettiva ed oncostatica preventiva, nei tumori del seno, dell'utero e nel melanoma.

Legal Events

Date Code Title Description
0001 Granted